Sunday, February 22, 2015 11:52:03 AM
Summary
ONCE develops gene therapy that targets debilitating genetic diseases.
The 25-day quiet period on ONCE will end 2.24.2015, allowing its IPO underwriters to publish reports and recommendations for the first time; this could lead to an uptick in price.
Recent research shows above-market returns in the days surrounding a firm's quiet period expiration, particularly for firm with strong underwriters, like ONCE.
We suggest investors strongly consider buying into ONCE, ahead of the event, for full gains.
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM